Naomi Kiyota

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

Medicine, Oncology, Metastasis +5

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer

Yoshinori Imamura, Toru Mukohara, Yohei Shimono et al. · Oncology Reports · 2015 · 858 citations · Full text

Medicine, Cancer Biology, Oncology +15

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 800 citations · Full text

Medicine, Oncology, Metastasis +14

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein et al. · The Lancet Oncology · 2017 · 430 citations · Full text

Medicine, Oncology, Pharmacotherapy +8